Less expense ratio implies better returns over the long term

Expense Ratio

ETF has been able to closely match its benchmark's returns

Tracking Error

ETF has been generating better price return than bank FD

Return vs FD Rates

Good time to consider, as ETF is not in overbought zone

Entry Point

The Nifty Pharma index closed 0.86 per cent at 22501.85.

Stock market update: Nifty Pharma index 0.86%

​So, there will still be uncertainties around and most of the IT stocks have had a very strong rally, like if you look at the larger ones, they have had a decent rally but many have virtually moved up in a straight line and today traded valuations which are two-three times historical earnings for some of the mid-tier companies which would be unsustainable in my view.

Sun Pharma and Dr. Reddy’s emerging as strong bets in pharma sector: Sandip Sabharwal

The Nifty Pharma index was trading 0.25 per cent at 22754.45.

Stock market update: Nifty Pharma index 0.25% in a weak market

When Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who think India will be unaffected, just do a Google search for “Trump on high import duty on Harley Davidson bikes”. A further indication came just a few days ago when he mentioned Brazil and India in the same breath, saying that the two countries were imposing high tariffs and should expect consequences. While it may not become a major issue, there may well be some retaliation. Or the threat of retaliation could be used as a tool to get India to change its stance on some global issue. Or as a quid pro quo: For instance, a push for lower duties on EVs, especially cars – a move that could help Trump’s biggest backer Elon Musk and his Tesla. But one sector which would be relatively safe could be pharma, and there are reasons for it. And mind you, we are using the word “ relatively”.Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardized scores. SR+ Reports is a complimentary offering to ETPrime members.

A Trump tariff tantrum-proof sector? 8 stocks from pharma sector, where Democrats and Republicans are in agreement, with an upside potential of up to 34% in 1 year

Select stocks gain momentum even in volatile markets.

Daily Trading Desk: 2 trades for short-term gains; two large-cap pharma stocks, both for around 6% rise

Neeraj Sharma discusses global geo-political concerns impacting CDMOs, emphasizing diversification and GLP-1 market opportunities in pharma industry.

Boardroom conversations focused on diversifying supply-chains, an opportunity for CDMOs, says OneSource chief

The Nifty Pharma index closed 1.72 per cent at 22697.90.

Stock market update: Nifty Pharma index 1.72%

The Nifty Pharma index was trading 1.01 per cent at 22541.00.

Stock market update: Nifty Pharma index 1.01% in a weak market

The acquisition supports Glenmarks goal of achieving carbon neutrality by 2030. The deal follows a Securities Subscription & Shareholders Agreement signed in May 2024 with O2 Renewable Energy XXIV and O2 Energy SG Pte. Ltd., involving an investment of Rs 1.99 crore through the purchase of equity shares and Compulsorily Convertible Debentures (CCDs).

Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIV

Market expert Dipan Mehta sees a corrective phase and advises holding 15-20% cash. He favors pharma stocks like Sun Pharma and Caplin Point. Mehta also highlights specialized retail companies as potential investments. He expresses caution but suggests a Nifty target of 26,000 for 2025. The cement sector is a no-go, and global uncertainties loom.

Market experiencing a prolonged sideways correction, hold 15-20% of portfolio in cash: Dipan Mehta

The Nifty Pharma index closed 1.09 per cent at 22314.55.

Stock market update: Nifty Pharma index 1.09%

The ETF tracks Nifty Pharma Index which is designed to reflect the behavior and performance of the pharmaceutical sector in India.